AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns

The harm to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's proceedings nonaccomplishment is little astir the numbers than astir a dent to management's credibility, according to Jefferies.

The shares fell 9% and topped the FTSE 100 fallers' list, a determination the broker expects to transcend the drug's existent publication to valuation.

Jefferies, which rates the banal a 'buy' with an 18,000p target, forecasts highest Wainua income successful the bosom denotation of $4 cardinal astatine a 60% probability.

That equates to astir 250p a stock of risk-adjusted value, oregon astir 2% of nett contiguous value.

The bank's blunt appraisal is that the archetypal stock terms determination volition apt beryllium treble that impact.

The crushed lies successful expectations. AstraZeneca is regarded arsenic susceptible of designing near-watertight trials, truthful a nonaccomplishment raises awkward questions.

Jefferies pointed to a circumstantial culprit: a 24% drop-in of rival cause tafamidis during the study, which lifted the stock of patients connected the competing attraction from 57% astatine the outset towards astir 80%.

That is good supra the 53% seen successful Pfizer's rival HELIOS-B trial, muddying Wainua's accidental of showing payment connected apical of existing therapy.

Encouragingly, patients connected Wainua unsocial showed a 29% simplification successful events, a nominally important effect broadly successful enactment with HELIOS-B.

Management had been highly assured of hitting the superior endpoint and demonstrating payment successful operation use, making the miss harder to explicate away.

The timing compounds the problem, the broker suggested.

Investors person small appetite for volatility events, and the adjacent large catalyst, the AVANZAR lung crab readout expected astir July oregon August, is itself contested.

Jefferies suspects the banal whitethorn not retrieve until that overhang clears.

Crucially, the nonaccomplishment does not endanger AstraZeneca's $80 cardinal 2030 income target, leaving the semipermanent concern lawsuit intact adjacent arsenic sentiment sours.